Abiomed, Inc.ABMDNASDAQ
Loading
| Metric | Q3 2021 | Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 |
|---|---|---|---|---|---|
| Revenue Growth | +18.30% | +12.74% | +11.86% | +9.73% | +7.16% |
| Gross Profit Growth | +19.43% | +12.07% | +11.90% | +8.26% | +6.26% |
| EBITDA Growth | +1.92% | -5.84% | +33.87% | -57.23% | +240.44% |
| Operating Income Growth | -1.47% | -9.51% | +3.50% | +0.00% | -4.04% |
| Net Income Growth | -8.45% | -26.05% | +6.10% | +0.00% | +86.35% |
| EPS Growth | -9.42% | -26.28% | +5.56% | +0.00% | +87.20% |
| EPS Diluted Growth | -8.82% | -25.93% | +5.65% | +0.00% | +87.10% |
| Weighted Average Shares Growth | +0.74% | +0.68% | +0.61% | +0.58% | -0.14% |
| Weighted Average Shares Diluted Growth | +0.51% | +0.47% | +0.35% | +1.35% | -0.40% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -21.55% | +14.35% | -8.68% | +23.02% | -77.84% |
| Free Cash Flow Growth | -21.20% | +17.64% | +6.15% | +27.25% | -85.36% |
| Receivables Growth | +10.70% | -4.34% | -6.76% | +2.77% | +5.48% |
| Inventory Growth | +3.34% | +9.40% | +15.94% | +14.00% | +18.90% |
| Asset Growth | +15.22% | +11.51% | +11.98% | +16.82% | +10.88% |
| Book Value per Share Growth | +16.24% | +12.83% | +12.37% | +16.81% | +11.37% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +34.45% | +23.83% | +36.88% | +7.34% | +2.55% |
| SG&A Expenses Growth | +29.83% | +24.85% | +9.20% | +14.02% | +13.80% |